Nyxoah Taps Teleflex Veteran Liam Kelly as CEO to Accelerate U.S. Expansion
Event summary
- Nyxoah appoints Liam Kelly as CEO effective October 1, 2026, succeeding Olivier Taelman.
- Kelly brings 25 years of MedTech leadership, most recently as CEO of Teleflex Incorporated.
- Appointment underscores Nyxoah’s strategic shift toward U.S.-focused commercialization post-FDA approval.
- Genio system, Nyxoah’s lead product, received FDA approval in August 2025 for OSA treatment.
The big picture
Nyxoah’s appointment of Liam Kelly signals a pivot toward aggressive U.S. commercialization, leveraging his experience in scaling MedTech businesses. The move comes as the company seeks to capitalize on FDA approval for its Genio system, positioning itself against established players in the sleep apnea treatment space. Kelly’s background in global medical technology leadership suggests a focus on operational efficiency and market expansion.
What we're watching
- Execution Risk
- How Kelly’s track record at Teleflex translates to scaling Nyxoah’s U.S. commercial operations.
- Market Penetration
- The pace at which Genio gains physician adoption and patient uptake in the competitive OSA market.
- Strategic Focus
- Whether Nyxoah can sustain its U.S. growth momentum while maintaining European market presence.